Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Bram De Laere, Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D’hondt, Rebecka Bergström, Venkatesh Chellappa, Markus Mayrhofer, Mahsan Banijamali, Anastasijia Kotsalaynen, Céline Schelstraete, Jan Pieter Vanwelkenhuyzen, Marie Hjälm-Eriksson, Linn Pettersson, Anders Ullén, Nicolaas Lumen, Gunilla Enblad, Camilla Thellenberg Karlsson, Elin Jänes, Johan Sandzén, Peter Schatteman, Maria Nyre Vigmostad, Martha Olsson, Christophe Ghysel, Brieuc Sautois, Wendy De Roock, Siska Van Bruwaene, Mats Anden, Ingrida Verbiene, Daan De Maeseneer, Els Everaert, Jochen Darras, Bjørg Y. Aksnessether, Daisy Luyten, Michiel Strijbos, Ashkan Mortezavi, Jan Oldenburg, Piet Ost, Martin Eklund, Henrik Grönberg, Johan Lindberg

Open source

DOI: 10.1038/s41591-024-03204-2
Published: 2024-08-20
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03204-2,
  title = {Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial},
  author = {Bram De Laere and Alessio Crippa and Andrea Discacciati and Berit Larsson and Maria Persson and Susanne Johansson and Sanne D’hondt and Rebecka Bergström and Venkatesh Chellappa and Markus Mayrhofer and Mahsan Banijamali and Anastasijia Kotsalaynen and Céline Schelstraete and Jan Pieter Vanwelkenhuyzen and Marie Hjälm-Eriksson and Linn Pettersson and Anders Ullén and Nicolaas Lumen and Gunilla Enblad and Camilla Thellenberg Karlsson and Elin Jänes and Johan Sandzén and Peter Schatteman and Maria Nyre Vigmostad and Martha Olsson and Christophe Ghysel and Brieuc Sautois and Wendy De Roock and Siska Van Bruwaene and Mats Anden and Ingrida Verbiene and Daan De Maeseneer and Els Everaert and Jochen Darras and Bjørg Y. Aksnessether and Daisy Luyten and Michiel Strijbos and Ashkan Mortezavi and Jan Oldenburg and Piet Ost and Martin Eklund and Henrik Grönberg and Johan Lindberg},
  year = {2024},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-024-03204-2},
  url = {https://doi.org/10.1038/s41591-024-03204-2}
}

RIS

TY  - JOUR
TI  - Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
AU  - Bram De Laere
AU  - Alessio Crippa
AU  - Andrea Discacciati
AU  - Berit Larsson
AU  - Maria Persson
AU  - Susanne Johansson
AU  - Sanne D’hondt
AU  - Rebecka Bergström
AU  - Venkatesh Chellappa
AU  - Markus Mayrhofer
AU  - Mahsan Banijamali
AU  - Anastasijia Kotsalaynen
AU  - Céline Schelstraete
AU  - Jan Pieter Vanwelkenhuyzen
AU  - Marie Hjälm-Eriksson
AU  - Linn Pettersson
AU  - Anders Ullén
AU  - Nicolaas Lumen
AU  - Gunilla Enblad
AU  - Camilla Thellenberg Karlsson
AU  - Elin Jänes
AU  - Johan Sandzén
AU  - Peter Schatteman
AU  - Maria Nyre Vigmostad
AU  - Martha Olsson
AU  - Christophe Ghysel
AU  - Brieuc Sautois
AU  - Wendy De Roock
AU  - Siska Van Bruwaene
AU  - Mats Anden
AU  - Ingrida Verbiene
AU  - Daan De Maeseneer
AU  - Els Everaert
AU  - Jochen Darras
AU  - Bjørg Y. Aksnessether
AU  - Daisy Luyten
AU  - Michiel Strijbos
AU  - Ashkan Mortezavi
AU  - Jan Oldenburg
AU  - Piet Ost
AU  - Martin Eklund
AU  - Henrik Grönberg
AU  - Johan Lindberg
PY  - 2024
JO  - Nature Medicine
DO  - 10.1038/s41591-024-03204-2
UR  - https://doi.org/10.1038/s41591-024-03204-2
ER  -

APA

Laere, B. D., Crippa, A., Discacciati, A., Larsson, B., Persson, M., Johansson, S., D’hondt, S., Bergström, R., Chellappa, V., Mayrhofer, M., Banijamali, M., Kotsalaynen, A., Schelstraete, C., Vanwelkenhuyzen, J. P., Hjälm-Eriksson, M., Pettersson, L., Ullén, A., Lumen, N., Enblad, G., Karlsson, C. T., Jänes, E., Sandzén, J., Schatteman, P., Vigmostad, M. N., Olsson, M., Ghysel, C., Sautois, B., Roock, W. D., Bruwaene, S. V., Anden, M., Verbiene, I., Maeseneer, D. D., Everaert, E., Darras, J., Aksnessether, B. Y., Luyten, D., Strijbos, M., Mortezavi, A., Oldenburg, J., Ost, P., Eklund, M., Grönberg, H., & Lindberg, J. (2024). Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03204-2

Source records

crossref · retrieved 2026-09-27T02:47:26.575Z